Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
QUINAGLUTE is an oral extended-release tablet approved in 1969 by Bayer as a small-molecule NDA. The specific indication and mechanism of action are not documented in available data. This is a legacy product with a long market history.
As loss of exclusivity approaches, brand teams are likely consolidating; expect reduced headcount and focus on generic transition strategy.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
QUINAGLUTE represents a mature, declining-franchise assignment with minimal linked job openings. Working on this product offers experience in mature-market management, generic transition strategy, and cost optimization—skills valuable in pharma's post-patent environment.
Worked on QUINAGLUTE at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.